This document is a tool to support regulatory authorities’ decisions on the hazard of specific chemicals when they receive test results from a Test Guideline (TG) or draft TG for the screening/testing of chemicals for endocrine disrupting properties.

Experienced physicians concisely explain the pathophysiology and clinical manifestations of endocrine disorders and survey all the latest laboratory diagnostics. Topics range widely from an overview of the diagnosis of diabetes and the long-term monitoring of its complications to the evaluation of menstrual dysfunction. Coverage is also given to the diagnosis of pituitary tumors, Cushing's syndrome, thyroid disease, and hypoglycemia; the evaluation of endocrine-induced hypertension; the assessment of dyslipidemia and obesity; and approaches to diagnosing hyper- and hypocalcemia. There are also discussions of osteoporosis, hypogonadism and erectile dysfunction, and hyperandrogenism in women. The authors each review the complex physiological basis of the relevant endocrine processes and provide richly instructive recommendations for followup and long-term management of patients.

This guidance document was originally published in 2012 and updated in 2018 to reflect new and updated OECD test guidelines, as well as reflect on scientific advances in the use of test methods and assessment of the endocrine activity of chemicals.

"Pescovitz and Eugster, both affiliated with the Section for Pediatric Endocrinology/Diabetology at Indiana University School of Medicine, provide essential information on the mechanisms, diagnosis, and management of pediatric endocrine disorders. Aspects of human development and physiology are combined with information on etiology, diagnosis, and treatment. Within each of the traditional endocrine systems, contemporary molecular genetics and developmental endocrinology are presented, followed by material on specific clinical disorders and therapeutic strategies. Interspersed throughout the book are chapters devoted to emerging issues such as childhood obesity, short stature, and treatment of children with disorders of sexual differentiation. B&w photos and diagnostic images are included. Annotation : 2004 Book News, Inc., Portland, OR (booknews.com)"--[source inconnue].

Many aspects of drug safety have become an outstanding and even persistent issue and may occur during the process of both drug discovery and development. Until 15 years ago, drug discovery and evaluation was primarily a sequential process starting with the selection of the most pharmacologically active compound from a series of newly synthesized small molecule chemical series by means of distinctive pharmacological assays. Safety aspects were addressed by evaluation of the selected compound at high doses in a series of specific studies directed at indications other than the intended indication of the new compound. These tests are then followed by pharmacokinetic studies, which are primarily conducted to confirm whether the selected compound possesses a suitable half-life for sufficient exposure and efficacy and, whether it has the desired properties specificity to the intended route of administration. Safety aspects relied predominantly on the conduct of single and repeat toxicologydose studies, which inform changes in organ structure rather than organ function. Both toxicological and pharmacokinetic studies are adapted to the progress of studies in clinical pharmacology and clinical trials. The new edition of this well and broadly accepted reference work contains several innovative and distinguished chapters. This "sequential" strategy has been abandoned with this new version of the book for several reasons: - Of the possible multitude of negative effects that novel drugs may impart on organ function, e.g. ventricular tachy-arrhythmia, many are detected too late in non-clinical studies to inform clinicians. On the other hand, negative findings in chronic toxicity studies in animals may turn out to be irrelevant for human beings. - New scientific approaches, e.g. high-throughput screening, human pluripotent stem cells, transgenic animals, knock-out animals, in silico models, pharmaco-genomics and pharmaco-proteomics, as well as Artificial Intelligence (AI) methods offered new possibilities. - There are several examples, that show that the "druggability" of compounds was considerably underestimated when the probability of success of a new project was assessed. The success rate in the pharmaceutical industry and the introduction of new chemical entities to the market per year dropped dramatically, whereas the development time for a new compound increased, sometimes exceeding the patent protection. Research and development scientists, involving the following changes, therefore adopted a change of strategy: - Parallel instead of sequential involvement of the various disciplines (multidimensional compound optimization). - The term "Safety Pharmacology" was coined. The International Conference on Harmonization (ICH) founded a Safety Pharmacology Working Group and the Safety Pharmacology Society (SPS) was launched. The discipline provided for evaluation, development and validation of a multitude of safety tests outlined in the 'Core Battery of Studies'. - Characterizing the exposure profile of a drug by conducting pharmacokinetic studies that evaluates the absorption, distribution, metabolism and excretion should to be investigated at an early stage of development as results contribute to the selection of a compound for further development. Advancements in Toxicology were achieved by the introduction of new methods, e.g., in silico methods, genetic toxicology, computational toxicology and AI. The book is a landmark in the continuously changing world of drug research and developments. As such, it is essential reading for many groups: not only for all students of pharmacology and toxicology but also for industry scientists and physicians, especially those involved in clinical trials of drugs, and for pharmacists who must know the safety requirements of drugs. The book is essential for scientists and managers in the pharmaceutical industry who are involved in drug discovery, drug development and decision making in the development process. In particular, the book will be of use to government institutions and committees working on official guidelines for drug evaluation worldwide.

Established for more than thirty years as one of the world's most widely read gynecology texts, Clinical Gynecologic Endocrinology and Infertility is now in its Eighth Edition. In a clear, user-friendly style enhanced by abundant illustrations, algorithms, and tables, the book provides a complete explanation of the female endocrine system and its disorders and offers practical guidance on evaluation and treatment of female endocrine problems and infertility. Major sections cover reproductive physiology, clinical endocrinology, contraception and infertility. This edition has a modern full-color design. A companion website includes the fully searchable text, image bank and links to PubMed references.

Mayo Clinic Internal Medicine Board Review, 10th edition, is designed to meet the needs of physicians-in-training and practicing clinicians by updating their knowledge of internal medicine and preparing them for the ABIM certification and maintenance-of-certification examinations in internal medicine. For the 10th edition, contributors were asked to map chapters according to ABIM goals. At least 50 percent of the material will be new, with the remainder changed and updated. The redesign is intended to cover all ABIM goals while streamlining the text to make it more user-friendly. Large chapters have been broken up into smaller content-oriented chapters to facilitate shorter, more focused study opportunities. This book is divided into subspecialty topics (eg, allergy, cardiology, dermatology, etc) and cross-content topics related to general internal medicine (eg, men's health, women's health, geriatrics, etc). Questions and answers have been pulled from the main text to a companion book of Q&As to facilitate study.

Clinical Urologic Endocrinology: Principles for Men’s Health provides an organized, accessible reference on men’s endocrinological health. Over 30 million men in the US alone suffer from erectile dysfunction and over 13 million men in the US suffer from hypogonadism (low testosterone). One out of seven couples also suffer from subfertility of which 50-60% have male factor involvement. More and more men are coming forward to seek treatment for such issues, which in the past were considered taboo and there is a strong need for a book which provides guidance for practitioners who support men in their reproductive and sexual concerns. This book covers in depth the key issues in male reproductive health in one easy-to-use resource. Clinical Urologic Endocrinology: Principles for Men’s Health is a valuable reference for urologists, endocrinologists, internal medicine physicians, family medicine physicians, sex therapists, and allied health professionals providing care for men in the areas of sexual health, fertility, and men’s endocrinological health.

Now in its second edition, the Oxford Textbook of Endocrinology and Diabetes is a fully comprehensive, evidence-based, and highly-valued reference work combining basic science with clinical guidance, and providing first rate advice on diagnosis and treatment.

Completely updated, the new edition of this easy-to-reference text examines the physiological, biochemical, and genetic aspects of pediatric endocrine disorders. Leaders in the field discuss the hottest topics-including genetics, diabetes and obesity-impacting today’s endocrine practice, keeping you up to date. A user-friendly organization speeds you to the information you need, and conceptual illustrations and photographs depict the latest advances with consistency and clarity. It’s the guidance you need to provide effective, state-of-the-art care for your pediatric and neonatal patients. Examines the physiological, biochemical, and genetic aspects of endocrine disorders all in one convenient reference. Incorporates the importance of molecular biology as it relates to developmental and pediatric endocrinology. Offers expanded coverage of genetics, diabetes and obesity-topics of increasing concern in pediatric endocrinology today. Presents the work of many new contributors for fresh perspectives on the current state of pediatric endocrinology. Provides new tables of normal values and growth charts for monitoring your patients’ progress. Concepts, Endocrine Disorders of the Newborn, Endocrine Disorders of Childhood and Adolescence, and Laboratory Tests and Imaging-making the material easy to navigate.